Last reviewed · How we verify
bortezomib and G-CSF
At a glance
| Generic name | bortezomib and G-CSF |
|---|---|
| Also known as | Velcade, Filgrastim |
| Sponsor | University of Kansas Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Peripheral sensory neuropathy
- Hemoglobin decreased
- Diarrhea
- Infection
- Leukocyte count decreased
- Acute GvHD
- Serum albumin decreased
- Lymphocyte count decreased
- Neutrophil count decreased
- Fever
- Platelet count decreased
Key clinical trials
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older (PHASE2)
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (PHASE2)
- Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) (PHASE3)
- Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease (PHASE4)
- MUK Nine b: OPTIMUM Treatment Protocol (PHASE2)
- Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma (PHASE1, PHASE2)
- Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bortezomib and G-CSF CI brief — competitive landscape report
- bortezomib and G-CSF updates RSS · CI watch RSS
- University of Kansas Medical Center portfolio CI